Recorded on: September 26, 2025
1.25 CME Credits for physicians and physician associates available until: October 28, 2026
1.25 CPE Contact hours for pharmacists available until: October 28, 2026
1.25 CE Credit/Contact hours for nurses available until: October 28, 2026
1.25 IPCE Credits available until: October 28, 2026
Format: Non-interactive recorded webinar
Download: Program Slides
Target Audience
This activity is intended for hematologists-oncologists, medical oncologists, physician associates, nurse practitioners, nurses and pharmacists involved in the care of patients with myeloma.
Description
This webinar will feature highlights from Myeloma Rounds in Durham, San Francisco, and Philadelphia that were held in the spring of 2025, as well as highlights of additional clinical updates after the Rounds. This discussion will highlight recent advances in myeloma, including emerging and approved therapies, clinical trials, evidence-based care strategies, and ongoing challenges in diagnosis and treatment. It will also include a review of educational resources for you, as well as resources to support your patient and their caregivers.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe the latest developments in myeloma, including current and emerging treatments
- Engage patients and caregivers in discussions on clinical trials, newly approved therapies and emerging therapies for myeloma, including combination therapies, CAR T-cell therapy and bispecific antibodies
- Explain disparities and challenges in diagnosis and treatment of myeloma
- Apply evidence-based treatment strategies for optimal patient care
- Identify patient support resources
Faculty
Ajai Chari, MD (Chair, Myeloma Rounds San Francisco)
Director of Multiple Myeloma Program
Co-Director of Clinical Research Hematology/Oncology
Professor of Clinical Medicine
University of California, San Francisco
San Francisco, CA
Edward A. Stadtmauer, MD (Chair, Myeloma Rounds, Philadelphia)
Section Chief, Hematologic Malignancies
Roseman, Tarte, Harrow, and Shaffer Families’
President’s Distinguished Professor
University of Pennsylvania Abramson Cancer Center
Philadelphia, PA
Cindy Varga, MD (Chair, Myeloma Rounds, Durham)
Associate Professor
Atrium Health Levine Cancer Institute
Plasma Cell Dyscrasia Division
Department of Hematology and Oncology
Charlotte, NC
Continuing Education Information
In support of improving patient care, this activity has been planned and implemented by Blood Cancer United and Medical Learning Institute Inc. Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
Physician Associate
Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Pharmacy
Medical Learning Institute Inc designates this application-based continuing education activity for 1.25 contact hours (0.1 25 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-25-038-H01-P
Registered Nursing Credit Designation
Approval for nurses has been obtained by the National Office of Blood Cancer United Society under Provider Number CEP 5832 to award 1.25 continuing education contact hours through the California Board of Registered Nursing.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity posttest, evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Nicole Dane via email at [email protected].
Providers
This activity is provided by Blood Cancer United and Medical Learning Institute Inc, in collaboration with the Association of Cancer Care Centers™ (ACCC).
Supporter Statement
Supported by educational grants from Adaptive Biotechnologies Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: [email protected].